Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2021-04-06 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
独立董事候选人声明（杨忠智）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of Zhejiang Tailin Biotechnology Co., Ltd. It contains detailed statements about the candidate's qualifications, compliance with relevant laws, regulations, and stock exchange rules, and assurances of independence. There is no financial data, no mention of financial results, no discussion of company performance, and no indication of a report or announcement of voting results. The content is focused on board/management information, specifically the candidacy and qualifications of an independent director. This fits the category of Board/Management Information (MANG). The document length is about 5,462 characters, which is sufficient for a detailed declaration but not a full report. Therefore, the classification is MANG with high confidence.
2021-04-06 Chinese
独立董事候选人声明（李继承）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Zhejiang Tailin Biotechnology Co., Ltd. It contains statements about the candidate's qualifications, compliance with laws and regulations, independence, and other criteria relevant to serving as an independent director. There is no financial data, no report of financial results, no voting results, no management changes, no legal proceedings, no capital updates, and no mention of any report publication. The content is focused on governance and compliance related to board membership qualifications. Therefore, this document fits best under Board/Management Information (MANG), as it relates to the announcement and declaration of a candidate for the board of directors.
2021-04-06 Chinese
关于使用部分闲置募集资金及自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the use of part of idle raised funds and own funds for cash management. It includes information about the approval process by the board of directors, supervisory board, independent directors, and the sponsor institution. The document discusses the use of idle funds from the initial public offering (IPO) proceeds, the investment types, risk control measures, and compliance with regulatory requirements. It is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory announcement about capital management activities related to fundraising proceeds and cash management. This fits best under the category of Capital/Financing Update (CAP), as it updates on the company's use of raised funds and capital management activities.
2021-04-06 Chinese
独立董事候选人声明（董明）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of Zhejiang Tailin Biotechnology Co., Ltd. It contains detailed statements about the candidate's qualifications, compliance with relevant laws and regulations, and independence criteria. There is no financial data, no discussion of company performance, no voting results, no management changes, and no mention of any report publication. The content is focused on the candidate's eligibility and compliance with regulatory requirements for serving as an independent director. This type of document is best classified under Board/Management Information (MANG), as it relates to board member candidacy and governance compliance.
2021-04-06 Chinese
独立董事关于第二届董事会第十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters related to the company's board meeting, specifically about board member nominations and the use of idle raised funds for cash management. It references compliance with regulatory guidelines and company articles but does not contain financial statements or detailed financial results. The document is a formal opinion related to board/management matters rather than a financial report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on governance and management decisions, not a full report or announcement of voting results.
2021-04-06 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司使用部分闲置募集资金及自有资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from the sponsor institution (长城证券股份有限公司) regarding the use of idle raised funds and own funds by 浙江泰林生物技术股份有限公司 for cash management. It includes regulatory references, approval procedures, risk control measures, and confirmation that the use complies with relevant laws and regulations. The document does not contain financial statements or quarterly/yearly financial results but is a formal verification and opinion report related to the use of funds raised in an IPO. It is not an announcement of a report publication but a substantive verification opinion. This fits the definition of an Audit Report / Information (AR), which includes standalone audit or verification reports and applied accounting or regulatory compliance information, excluding full annual or interim reports. FY 2021
2021-04-06 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.